Comparative Pharmacology
Head-to-head clinical analysis: BUSPAR versus MEPROSPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSPAR versus MEPROSPAN.
BUSPAR vs MEPROSPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at serotonin 5-HT1A receptors, leading to reduced serotonergic activity; also has antagonist activity at D2 and 5-HT2 receptors.
Meprobamate is a carbamate derivative that acts as a central nervous system depressant. It potentiates GABA-A receptor activity and inhibits excitatory neurotransmitter release, leading to anxiolytic, sedative, and muscle relaxant effects.
Initial: 7.5 mg orally twice daily; may increase by 5 mg/day every 2-3 days. Usual: 20-30 mg/day in divided doses; max 60 mg/day.
Meprobamate: 400-600 mg orally 3-4 times daily, maximum 2400 mg/day.
None Documented
None Documented
2–3 hours (terminal); clinical context: requires multiple daily dosing; steady-state achieved in ~2 days
Terminal elimination half-life: 15 hours. Steady state reached after 3-5 days. No active metabolites.
Renal: 29–63% (primarily as metabolites, <1% unchanged); Fecal: 34–38%; Biliary: minimal
Renal: 70% as inactive metabolites; fecal: 20% as conjugated metabolites; biliary: 10%.
Category C
Category C
Anxiolytic
Anxiolytic